UC Berkeley’s cell therapy developer has filed for an initial public offering.
Caribou Biosciences, a US-based gene therapy developer spun out of University of California (UC) Berkeley, has filed for an initial public offering.
Founded in 2011, Caribou is using Crispr genome editing technology to develop modified cell therapies for the treatment of haematologic cancers and solid tumours.
It plans to use the IPO proceeds to fund the development of its chimeric antigen receptors (CAR) T-cell and natural killer (NK) cell therapies.
The spinout was co-founded by Jennifer…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
